Literature DB >> 24314055

Quantitative FDG PET/CT in the community: experience from interpretation of outside oncologic PET/CT exams in referred cancer patients.

Abdel K Tahari1, Richard L Wahl.   

Abstract

PURPOSE: Tertiary care institutions often deal with patients who have had a baseline positron emission tomography (PET)/computed tomography (CT) scan performed elsewhere. Little data exist regarding the quality of these PET/CT scans and whether they are fully suitable for qualitative or quantitative interpretation. We evaluated outside PET/CT scans from cancer patients referred to our institution and compared them with PET/CT scans acquired locally.
METHODS: This Health Insurance Portability and Accountability Act-compliant retrospective study was approved by our institutional review board. Informed consent requirements were waived. One hundred seventy recent whole-body outside PET/CT exams from many sites were digitally imported into our radiology imaging system and reviewed for key quality metrics including time from injection until imaging, availability of patient height and weight information, serum glucose level and [(18) F]fluoro-2-deoxy-D-glucose (FDG) dose. The standardised uptake value (SUV) and SUV based on lean body mass (SUL) in the liver were measured whenever possible. These were compared with 170 internal studies performed at our centre during the same period.
RESULTS: Missing data were common in outside scans with height in 62%, weight 35%, uptake time 25%, FDG dose 28% and glucose levels in 64% of cases. In quantitatively evaluable cases, mean liver SUL, SUV, FDG dose and uptake time were much more variable in outside than in internal studies.
CONCLUSION: Approximately one-third of the outside PET/CT studies submitted digitally for analysis lacked key information required to secure any quantitative imaging data. Only about a third of these studies had all necessary information available for accurate SUL determination and had acceptable quality that was comparable with locally acquired scans. This suggests that many of PET studies performed in the community cannot be relied upon to provide quantitative image data that can be applied in a different centre. Greater standardisation of oncologic PET/CT studies among different centres must still be pursued.
© 2013 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  FDG; PET/CT; SUV; quantitative PET; standardisation

Mesh:

Substances:

Year:  2013        PMID: 24314055      PMCID: PMC3975673          DOI: 10.1111/1754-9485.12140

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  15 in total

1.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

Review 2.  Use of PET for monitoring cancer therapy and for predicting outcome.

Authors:  Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

3.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

4.  Is liver SUV stable over time in ¹⁸F-FDG PET imaging?

Authors:  Eric Laffon; Xavier Adhoute; Henri de Clermont; Roger Marthan
Journal:  J Nucl Med Technol       Date:  2011-08-30

Review 5.  Techniques and applications of automatic tube current modulation for CT.

Authors:  Mannudeep K Kalra; Michael M Maher; Thomas L Toth; Bernhard Schmidt; Bryan L Westerman; Hugh T Morgan; Sanjay Saini
Journal:  Radiology       Date:  2004-10-21       Impact factor: 11.105

6.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

7.  Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.

Authors:  Nancy Paquet; Adelin Albert; Jacqueline Foidart; Roland Hustinx
Journal:  J Nucl Med       Date:  2004-05       Impact factor: 10.057

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose.

Authors:  Yuji Nakamoto; Kenneth R Zasadny; Heikki Minn; Richard L Wahl
Journal:  Mol Imaging Biol       Date:  2002-03       Impact factor: 3.488

Review 10.  Strategies for reducing radiation dose in CT.

Authors:  Cynthia H McCollough; Andrew N Primak; Natalie Braun; James Kofler; Lifeng Yu; Jodie Christner
Journal:  Radiol Clin North Am       Date:  2009-01       Impact factor: 2.303

View more
  8 in total

1.  Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials.

Authors:  Frank Hofheinz; Ivayla Apostolova; Liane Oehme; Jörg Kotzerke; Jörg van den Hoff
Journal:  J Nucl Med       Date:  2017-05-04       Impact factor: 10.057

2.  Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.

Authors:  Jason M Williams; Sudheer D Rani; Xia Li; Lori R Arlinghaus; Tzu-Cheng Lee; Lawrence R MacDonald; Savannah C Partridge; Hakmook Kang; Jennifer G Whisenant; Richard G Abramson; Hannah M Linden; Paul E Kinahan; Thomas E Yankeelov
Journal:  Med Phys       Date:  2015-07       Impact factor: 4.071

Review 3.  Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials.

Authors:  Joshua S Scheuermann; Janet S Reddin; Adam Opanowski; Paul E Kinahan; Barry A Siegel; Lalitha K Shankar; Joel S Karp
Journal:  J Nucl Med       Date:  2017-03-02       Impact factor: 10.057

4.  An account of data entry inconsistencies and their impact on positron emission tomography quantification.

Authors:  Tram Nguyen; Christina Baun; Poul Flemming Høilund-Carlsen
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  Correction of scan time dependence of standard uptake values in oncological PET.

Authors:  Jörg van den Hoff; Alexandr Lougovski; Georg Schramm; Jens Maus; Liane Oehme; Jan Petr; Bettina Beuthien-Baumann; Jörg Kotzerke; Frank Hofheinz
Journal:  EJNMMI Res       Date:  2014-04-03       Impact factor: 3.138

6.  Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET.

Authors:  Frank Hofheinz; Jörg van den Hoff; Ingo G Steffen; Alexandr Lougovski; Kilian Ego; Holger Amthauer; Ivayla Apostolova
Journal:  EJNMMI Res       Date:  2016-06-22       Impact factor: 3.138

7.  An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET.

Authors:  Frank Hofheinz; Rebecca Bütof; Ivayla Apostolova; Klaus Zöphel; Ingo G Steffen; Holger Amthauer; Jörg Kotzerke; Michael Baumann; Jörg van den Hoff
Journal:  EJNMMI Res       Date:  2016-03-02       Impact factor: 3.138

8.  Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management.

Authors:  Peter Sawan; Karim Rebeiz; Heiko Schoder; Connie Batlevi; Alison Moskowitz; Gary A Ulaner; Mark Dunphy; Lorenzo Mannelli
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.